HMGB1 and impulse control disorder: Small‐molecule ICD inducers and other treatments: In 2020, Yamazaki et al.[168, 169] first demonstrated that PT‐112 acts as a novel platinum–pyrophosphate conjugate with cytotoxic effects that are similar to those of nanoparticle‐associated molecular pattern signaling, including in exposure of CRT and secretion of ATP and HMGB1, which drive ICD and exert antitumor immune effects (Figure 10).